Last reviewed · How we verify

Autologous Intrathecal Hematopoietic Stem Cells

Hospital Universitario Dr. Jose E. Gonzalez · Phase 3 active Biologic

Autologous Intrathecal Hematopoietic Stem Cells is a Cell therapy Biologic drug developed by Hospital Universitario Dr. Jose E. Gonzalez. It is currently in Phase 3 development for Spinal cord injury, Amyotrophic lateral sclerosis (ALS).

Autologous hematopoietic stem cells are harvested from the patient, processed, and reinfused intrathecally into the cerebrospinal fluid to promote neural repair and regeneration.

Autologous hematopoietic stem cells are harvested from the patient, processed, and reinfused intrathecally into the cerebrospinal fluid to promote neural repair and regeneration. Used for Spinal cord injury, Amyotrophic lateral sclerosis (ALS).

At a glance

Generic nameAutologous Intrathecal Hematopoietic Stem Cells
SponsorHospital Universitario Dr. Jose E. Gonzalez
Drug classCell therapy
ModalityBiologic
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

This cell therapy involves collecting the patient's own bone marrow-derived hematopoietic stem cells, which are then administered directly into the intrathecal space (around the spinal cord). These stem cells are believed to promote neuroprotection, reduce inflammation, and stimulate endogenous repair mechanisms in neurological tissues. The autologous approach minimizes immunological rejection while leveraging the regenerative potential of stem cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Autologous Intrathecal Hematopoietic Stem Cells

What is Autologous Intrathecal Hematopoietic Stem Cells?

Autologous Intrathecal Hematopoietic Stem Cells is a Cell therapy drug developed by Hospital Universitario Dr. Jose E. Gonzalez, indicated for Spinal cord injury, Amyotrophic lateral sclerosis (ALS).

How does Autologous Intrathecal Hematopoietic Stem Cells work?

Autologous hematopoietic stem cells are harvested from the patient, processed, and reinfused intrathecally into the cerebrospinal fluid to promote neural repair and regeneration.

What is Autologous Intrathecal Hematopoietic Stem Cells used for?

Autologous Intrathecal Hematopoietic Stem Cells is indicated for Spinal cord injury, Amyotrophic lateral sclerosis (ALS).

Who makes Autologous Intrathecal Hematopoietic Stem Cells?

Autologous Intrathecal Hematopoietic Stem Cells is developed by Hospital Universitario Dr. Jose E. Gonzalez (see full Hospital Universitario Dr. Jose E. Gonzalez pipeline at /company/hospital-universitario-dr-jose-e-gonzalez).

What drug class is Autologous Intrathecal Hematopoietic Stem Cells in?

Autologous Intrathecal Hematopoietic Stem Cells belongs to the Cell therapy class. See all Cell therapy drugs at /class/cell-therapy.

What development phase is Autologous Intrathecal Hematopoietic Stem Cells in?

Autologous Intrathecal Hematopoietic Stem Cells is in Phase 3.

What are the side effects of Autologous Intrathecal Hematopoietic Stem Cells?

Common side effects of Autologous Intrathecal Hematopoietic Stem Cells include Injection site pain or discomfort, Headache, Fever, Infection at injection site.

Related